A combined launch vehicle and satellite system
US-2024051685-A1 · Feb 15, 2024 · US
US10076481B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10076481-B2 |
| Application number | US-201715587265-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 4, 2017 |
| Priority date | May 5, 2016 |
| Publication date | Sep 18, 2018 |
| Grant date | Sep 18, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compositions comprising serine and an organic mono- or multi-phosphate salt and methods of using such compositions to treat and/or prevent periodontal disease and/or dental calculus are provided.
Opening claim text (preview).
What is claimed is: 1. An oral composition for treating periodontitis and dental calculus accumulation, comprising: serine at a concentration of between about 6.7 and about 238 mM; at least one organic mono-phosphate or multi-phosphate salt at a concentration of between about 3 and about 6 mM; a buffer providing the composition with a pH of between about 6.1 and about 7.0; and an orally acceptable dosage form, wherein introduction of the composition to the oral environment of a subject suffering from periodontitis or dental calculus accumulation, reduces the alkalinity and thereby increases calcium concentration in the saliva by dissolving the calculus. 2. The oral composition of claim 1 , wherein the orally acceptable dosage form is selected from the group consisting of toothpaste, gum, mouthwash and chewable tablets. 3. The oral composition of claim 1 , wherein the orally acceptable dosage form is a dentrifice or toothpaste. 4. The oral composition of claim 1 , wherein the pH of the composition is between about 6.1 and about 6.3. 5. The oral composition of claim 1 , wherein the pH of the composition is between about 6.7 and about 7.0. 6. The oral composition of claim 1 , wherein the organic mono-phosphate or multi-phosphate salt is an organic salt. 7. The oral composition of claim 6 , wherein the salt is an inositol. 8. The oral composition of claim 7 , wherein the inositol is a phytate. 9. The oral composition of claim 8 , wherein the phytate is sodium phytate. 10. The oral composition of claim 1 , wherein the orally acceptable dosage form is selected from the group consisting of capsule, tablet, emulsion, aqueous suspension, dispersion, paste, powder, gum, and solution. 11. The oral composition of claim 1 , wherein the orally acceptable dosage form comprises one or more carriers, one or more lubricating agents, or one or more diluents. 12. The oral composition of claim 11 , wherein the carrier is lactose or corn starch, the lubricating agent is magnesium stearate, and the diluent is lactose or dried corn starch. 13. The oral composition of claim 1 , wherein the orally acceptable dosage form comprises one or more sweetening, flavoring, or coloring agents. 14. A method of treating plaque or periodontal disease, the method comprising administering an effective amount of the oral composition of claim 1 to a subject having, or at risk of having, plaque or periodontal disease. 15. The method of claim 14 , wherein the subject is a human. 16. The method of claim 14 , wherein the periodontal disease is gingivitis. 17. The method of claim 14 , wherein the oral composition is applied to one or more teeth of the subject. 18. The method of claim 17 , wherein the oral composition is applied to the exposed enamel, dentine, or cementum of one or more teeth of the subject. 19. The method of claim 14 , wherein about 0.00001, 0.0001, 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.25, 1.5, 1.75, 2, 2.5, or 3-10000 mg/kg of serine is administered per day. 20. The method of claim 14 , wherein about 0.00001, 0.0001, 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.25, 1.5, 1.75, 2, 2.5, or 3-10000 mg/kg of at least one organic mono-phosphate or multi-phosphate salt is administered per day. 21. The oral composition of claim 1 , wherein the oral composition further comprises a device. 22. The oral composition of claim 21 , wherein the device is selected from the group consisting of brush, floss, flosser, irrigator, mouth guard, pick, retainer, scraper, spatula, and stick. 23. An oral composition consisting of serine, at least one organic mono-phosphate or multi-phosphate salt and a buffer providing a pH of between about 6.0 and about 9.5, in an orally acceptable dosage form.
Arrangements or adaptations of propulsion systems · CPC title
Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof · CPC title
Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof · CPC title
Starch; Amylose; Amylopectin; Derivatives thereof · CPC title
Phosphorus compounds · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.